| |  Online-Ressource |
|---|
| Verfasst von: | Rücker, Frank Gert [VerfasserIn]  |
|---|
| | Bullinger, Lars [VerfasserIn] |
|---|
| | Cocciardi, Sibylle [VerfasserIn] |
|---|
| | Skambraks, Sabrina [VerfasserIn] |
|---|
| | Luck, Tamara J. [VerfasserIn] |
|---|
| | Weber, Daniela [VerfasserIn] |
|---|
| | Krzykalla, Julia [VerfasserIn] |
|---|
| | Pozek, Ema [VerfasserIn] |
|---|
| | Schneider, Isabelle [VerfasserIn] |
|---|
| | Corbacioglu, Andrea [VerfasserIn] |
|---|
| | Gaidzik, Verena I. [VerfasserIn] |
|---|
| | Meid, Annika [VerfasserIn] |
|---|
| | Aicher, Sophia [VerfasserIn] |
|---|
| | Stegelmann, Frank [VerfasserIn] |
|---|
| | Schrade, Anika [VerfasserIn] |
|---|
| | Theis, Frauke [VerfasserIn] |
|---|
| | Fiedler, Walter [VerfasserIn] |
|---|
| | Salih, Helmut R. [VerfasserIn] |
|---|
| | Wulf, Gerald [VerfasserIn] |
|---|
| | Salwender, Hans [VerfasserIn] |
|---|
| | Schroeder, Thomas [VerfasserIn] |
|---|
| | Götze, Katharina S. [VerfasserIn] |
|---|
| | Kühn, Michael W. M. [VerfasserIn] |
|---|
| | Lübbert, Michael [VerfasserIn] |
|---|
| | Schlenk, Richard Friedrich [VerfasserIn] |
|---|
| | Benner, Axel [VerfasserIn] |
|---|
| | Thol, Felicitas [VerfasserIn] |
|---|
| | Heuser, Michael [VerfasserIn] |
|---|
| | Ganser, Arnold [VerfasserIn] |
|---|
| | Döhner, Hartmut [VerfasserIn] |
|---|
| | Döhner, Konstanze [VerfasserIn] |
|---|
| Titel: | Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin |
|---|
| Verf.angabe: | Frank G. Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks, Tamara J. Luck, Daniela Weber, Julia Krzykalla, Ema Pozek, Isabelle Schneider, Andrea Corbacioglu, Verena I. Gaidzik, Annika Meid, Sophia Aicher, Frank Stegelmann, Anika Schrade, Frauke Theis, Walter Fiedler, Helmut R. Salih, Gerald Wulf, Hans Salwender, Thomas Schroeder, Katharina S. Götze, Michael W.M. Kühn, Michael Lübbert, Richard F. Schlenk, Axel Benner, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, and Konstanze Döhner |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | December 10 2024 |
|---|
| Umfang: | 14 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Veröffentlicht: 3. Dezember 2024 ; Gesehen am 10.06.2025 |
|---|
| Titel Quelle: | Enthalten in: Blood advances |
|---|
| Ort Quelle: | Washington, DC : American Society of Hematology, 2016 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 8(2024), 23 vom: Dez., Seite 6067-6080 |
|---|
| ISSN Quelle: | 2473-9537 |
|---|
| Abstract: | Measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITDpos) has been hampered by the broad heterogeneity of ITD mutations. Using our recently developed FLT3-ITD paired-end next-generation sequencing (NGS)-based MRD assay (limit of detection 10−4 to 10−5), we evaluated the prognostic impact of MRD at different time points in 157 patients with FLT3-ITDpos AML who were enrolled in the German-Austrian Acute Myeloid Leukemia Study Group 16-10 trial and who were treated with a combination of intensive chemotherapy and midostaurin, followed by midostaurin maintenance. MRD negativity (MRDneg) after 2 cycles of chemotherapy (Cy2), which was observed in 111 of 142 (78%) patients, was predictive of superior 4-year rates of cumulative incidence of relapse (CIR) (4y-CIR; 26% vs 46%; P = .001) and overall survival (OS) (4y-OS; 70% vs 44%; P = .012). This survival advantage was also seen among patients who underwent allogeneic hematopoietic-cell transplantation during first complete remission (4y-CIR, 14% vs 39%; P = .001; 4y-OS, 71% vs 49%; P = .029). Multivariate models for CIR and OS after Cy2 revealed FLT3-ITD MRDneg as the only consistent favorable variable for CIR (hazard ratio [HR], 0.29; P = .006) and OS (HR, 0.39; P = .018). During follow-up, conversion from MRDneg to MRD positivity (MRDpos) was a strong, independent factor for inferior CIR (HR, 16.64; P < .001) and OS (HR, 4.05; P < .001). NGS-based FLT3-ITD MRD monitoring identifies patients at high risk for relapse and death following treatment with intensive chemotherapy and midostaurin. Using NGS-based technology. |
|---|
| DOI: | doi:10.1182/bloodadvances.2024013758 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1182/bloodadvances.2024013758 |
|---|
| | DOI: https://doi.org/10.1182/bloodadvances.2024013758 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1927860741 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin / Rücker, Frank Gert [VerfasserIn]; December 10 2024 (Online-Ressource)
